On February 3, 2024, the Food and Drug Administration (FDA) issued a critical warning to consumers, urging them not to purchase or use below mentioned eye drops due to the significant risk of eye infection.
- South Moon
- Rebright
- FivFivGo
This cautionary advisory was prompted by the FDA’s commitment to ensuring the safety and well-being of the general public.
The FDA’s vigilance in alerting consumers to the potential dangers associated with these specific eye drop products reflects its overarching mission to protect public health. By divulging crucial information about the potential risks of South Moon, Rebright, and FivFivGo eye drops, the FDA aims to empower consumers to make informed decisions and prioritize their eye health and safety.
As highlighted by the FDA’s warning to consumers, the potential risks associated with using South Moon, Rebright, and FivFivGo eyedrops include the heightened risk of eye infections. These products have been flagged due to concerns regarding possible eye infections that could result in partial vision loss or even blindness. The specifically identified risk of eye infections underscores the critical importance of avoiding these eye drop products to safeguard eye health and overall well-being.
South Moon, Rebright and FivFivGo eye drops are sold online, and claim to treat eye conditions such as glaucoma — but they are unapproved drugs and should not even be available for sale in the U.S., says the FDA.
The South Moon eye drops were contaminated with Burkholderia cepacia complex, a group of bacteria that could result in an antibiotic-resistant infection. FDA testing of the Rebright and South Moon eye drops also found that these copycat products lacked brimonidine tartrate, the active ingredient in Lumify.
South Moon is labeled as made by Shantou Cross-border Premium Products E-Commerce Co. Ltd. in China.
References:
https://www.goodhousekeeping.com/health/a43399552/eye-drops-recall-2023-brands-full-list